Tagged with clinical trials,

Korea Deborah Chee, President of KoNECT (Korea National Enterprise for Clinical Trials), discusses what it takes to build one of the world’s leading clinical trials ecosystems and highlights the importance of partnerships and collaborations between different stakeholders in Korea as a key factor in making it such a strategic destination for both…

Korea Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals how Daiichi Sankyo Korea plans to embrace the company’s global strategy of expanding into the new area of oncology.  …

USA PJ Brooks PhD, program director in the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) in the USA, highlights the importance of going beyond one disease at a time in clinical trials, some of the roadblocks that still remain…

Malaysia Click here to download the Healthcare & Life Sciences Review Malaysia 2018. After recent elections conducted in May 2018 saw Mahathir Mohamad returning as Prime Minister after 15 years to seal a historic victory, Malaysia is again back on its feet. Bolstered by well-established institutions, a fully-functional IP framework and strong…

Malaysia A map showing 18 of the active clinical trials sites in Malaysia in 2017. The sites are spread across the entire nation and cover a variety of therapeutic areas – including gastroenterology / hepatology, cardiology and oncology –  with a cluster of activity in Kuala Lumpur.   In terms of…

Malaysia Malaysia’s multi-ethnic population, disease burden, medical infrastructure and research speed, combined with its population’s proficiency in English, make the Southeast Asian nation a potentially excellent regional clinical trials destination.   We have a population of 32 million which represents a third of the world’s genomics Dr Akhmal Yusof, CRM Dr…

Algeria Radwa Terbeche, general manager of Amgen in Algeria discusses the potential for biosimilars in Algeria and the company’s role in developing a local clinical research infrastructure.   What has been your journey to becoming country manager of Amgen Algeria? By education I am a pharmacist specialized in industry. After graduating,…

Turkey Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to life-changing innovation. He also pinpoints MSD’s exceptional and enduring commitment to Turkey, which has led the company to emerge as…

Portugal Paulo Teixeira shines a light on Pfizer’s promising pipeline for 2018, the market access environment in Portugal and the clinical trial landscape. Teixeira intends to contribute to improving society’s perception of the pharmaceutical industry and position Pfizer as a partner for health and wellbeing in Portugal; part of the solution—not…

Ecuador Angel Guevara, molecular biologist and professor at the Central University of Ecuador (UCE), discusses Ecuador’s potential as a clinical trial destination, a diverse tropical country with high prevalence of infectious disease and educated healthcare professionals. He explains the differences between public and private healthcare services, notably from the point of…

Lithuania Martynas Jocys, Baltics marketing director and Lithuania general manager at AstraZeneca, talks about the role that innovation has played in the company’s strategy, the need for increased patient access in Lithuania and the other Baltic countries as well as the launch of new products for oncology, biologics, severe asthma, diabetes,…

Poland Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the first ever CDK8 inhibitor for acute myeloid leukaemia with great opportunities for further indications and development. Furthermore, he highlights the…